Oncology Sales Leader | President's Club Winner | Committed to Changing the Cancer Narrative
Such a huge win for ALK-positive NSCLC patients!! Patients will only benefit if we’re testing UPFRONT at first-line. Guardant CDx can provide that opportunity in less than 7 days. #alkpositive #nsclc #guardanthealth #concurrenttesting #liquidbiopsy #NCCNguidelines
Epic moment today for Pfizer Oncology: “After 5 years of follow-up, median PFS has yet to be reached in the lorlatinib group, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumors. These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced ALK-positive NSCLC and set a new benchmark for targeted therapies in cancer” #ASCO2024 #Lungcancer #Oncology #PFEcolleague